Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19661281 | 0.88 | MAOB (0.49) | MAOBHPGDPKMALDH1A1MEN1 | |
| SCHEMBL11327841 | 0.83 | HPGD (0.58) | HPGDPKMALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL20136969 | 0.83 | MAOB (0.40) | MAOBHPGDPKMALDH1A1MAPT | |
| SCHEMBL20168764 | 0.82 | MAOB (0.43) | MAOBHPGDPKMALDH1A1MAPT | |
| SCHEMBL14554544 | 0.81 | MAOB (0.49) | MAOBSMN1; SMN2 | |
| SCHEMBL3464887 | 0.81 | MAOB (0.47) | MAOBHPGDPKMALDH1A1MAPT | |
| SCHEMBL30469020 | 0.80 | MALT1 (0.50) | MAOB | |
| SCHEMBL25936957 | 0.80 | MALT1 (0.50) | MAOB | |
| SCHEMBL12638925 | 0.78 | KMT2A (0.61) | HPGDPKMALDH1A1MAPTACHE | |
| SCHEMBL30143437 | 0.77 | MEN1 (0.52) | ALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134674-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | MAOB 1755/4885HPGD 2748/4885PKM 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.